Fibrates, glitazones, and peroxisome proliferator-activated receptors. - Archive ouverte HAL Access content directly
Journal Articles Arteriosclerosis, Thrombosis, and Vascular Biology Year : 2010

Fibrates, glitazones, and peroxisome proliferator-activated receptors.

(1) , (1)
1

Abstract

Several decades ago, fibrates were approved for the treatment of dyslipidemia, whereas thiazolidinediones were screened in animal models to improve glucose homeostasis and were subsequently developed for the treatment of type 2 diabetes mellitus. Relatively recently, these drugs were found to act via peroxisome proliferator-activated receptors, nuclear receptors that control lipid metabolism and glucose homeostasis. In this historical perspective, we discuss the history of discovery of the peroxisome proliferator-activated receptors, from the clinical development of their agonists to the subsequent discovery of these receptors and their mechanisms of action, to finally evoke possibilities of targeted pharmacology for future development of selective peroxisome proliferator-activated receptor modulators.
Fichier principal
Vignette du fichier
inserm-00475566_edited.pdf (147.36 Ko) Télécharger le fichier
Vignette du fichier
LalloyerStaels_HistoryPPARs.pdf (125.59 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00475566 , version 1 (02-11-2010)

Identifiers

Cite

Fanny Lalloyer, Bart Staels. Fibrates, glitazones, and peroxisome proliferator-activated receptors.. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30 (5), pp.894-9. ⟨10.1161/ATVBAHA.108.179689⟩. ⟨inserm-00475566⟩
76 View
639 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More